Trial Profile
A randomized, double-blind, placebo-controlled Phase 1 trial of TERN-101 in the healthy male and female participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs TERN-101 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Terns Pharmaceuticals
- 16 Aug 2021 According to a Terns Pharmaceuticals media release, data from the study is accepted for publication in Clinical Pharmacology in Drug Development.
- 19 Feb 2020 Results presented in the Terns Pharmaceuticals Media Release.
- 19 Feb 2020 Status changed from recruiting to completed, according to a Terns Pharmaceuticals media release.